MCID: HPT023
MIFTS: 94

Hepatocellular Carcinoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Liver diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 53 37 12 72 55 71 36 28 13 51 14
Liver Cancer 53 12 71 40 14
Hcc 53 12 55 71
Hepatoma 53 12 71
Adult Primary Hepatocellular Carcinoma 12 69
Primary Malignant Neoplasm of Liver 12 69
Malignant Neoplasm of Liver 12 69
Hepatoblastoma, Somatic 53 13
Liver Cell Carcinoma 53 71
Primary Liver Cancer 12 49
Liver Neoplasms 41 69
Hepatic Cancer 12 51
Hepatoblastoma 55 69
Liver Neoplasm 12 14
Lcc 53 71
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 49
Hepatocellular Carcinoma, Childhood Type, Somatic 53
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 69
Resectable Malignant Neoplasm of the Liver 12
Malignant Neoplasm of Liver Unspecified 12
Primary Malignant Neoplasm of Liver Nos 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 53
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 49
Malignant Hepatobiliary Neoplasm 69
Hepatocellular Cancer, Somatic 53
Primary Tumor of the Liver 49
Liver Cell Carcinoma; Lcc 53
Carcinoma, Hepatocellular 41
Malignant Tumor of Liver 12
Primary Cancer of Liver 49
Primary Liver Carcinoma 49
Cancer, Hepatocellular 53
Hepatocellular Cancer 71
Neoplasm of the Liver 28
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 69
Adult Hepatoma 12

Characteristics:

Orphanet epidemiological data:

55
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

OMIM:

53
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

31
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous autosomal dominant inheritance


Classifications:

Orphanet: 55  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to childhood hepatocellular carcinoma and adult hepatocellular carcinoma, and has symptoms including fatigue, dyspnea and fever. An important gene associated with Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Feridex I.V. and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

OMIM : 53 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

UniProtKB/Swiss-Prot : 71 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 72 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 childhood hepatocellular carcinoma 35.1 CTNNB1 MET
2 adult hepatocellular carcinoma 34.8 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
3 hepatoblastoma 32.1 AFP APC CTNNB1 HNF1A MET
4 hepatic adenomas, familial 31.9 AFP APC CTNNB1 HNF1A
5 intrahepatic cholangiocarcinoma 31.9 AFP CTNNB1 TP53
6 adenocarcinoma 31.8 CTNNB1 HRAS MET TP53 VEGFA
7 gastric cancer 31.4 AFP APC CTNNB1 HRAS MET PIK3CA
8 colorectal cancer 31.4 APC AXIN1 CASP8 CTNNB1 HRAS IGF2R
9 familial adenomatous polyposis 31.4 APC AXIN1 CTNNB1 TP53
10 esophageal cancer 31.2 CTNNB1 HRAS PIK3CA TERT TP53 VEGFA
11 prostate cancer 31.1 CASP8 CDKN3 CTNNB1 HRAS MET PIK3CA
12 glioblastoma 31.0 HRAS MET PIK3CA TP53 VEGFA
13 acinar cell carcinoma 31.0 AFP APC CTNNB1 TP53
14 breast cancer 30.9 APC CASP8 CTNNB1 HRAS IGF2R MET
15 kidney cancer 30.9 MET PIK3CA TP53 VEGFA
16 thyroid cancer, nonmedullary, 1 30.8 APC CTNNB1 HRAS MET PIK3CA
17 pancreas adenocarcinoma 30.8 CTNNB1 HRAS TP53 VEGFA
18 colorectal adenocarcinoma 30.8 CTNNB1 HRAS TP53 VEGFA
19 gastric adenocarcinoma 30.7 AFP CTNNB1 HRAS MET
20 familial adenomatous polyposis 1 30.7 APC CTNNB1
21 cervical cancer 30.6 CASP8 HRAS PIK3CA TERT TP53
22 mixed fibrolamellar hepatocellular carcinoma 12.4
23 fibrolamellar carcinoma 12.2
24 aflatoxins-related hepatocellular carcinoma 12.0
25 ruijs-aalfs syndrome 11.8
26 leukoencephalopathy, brain calcifications, and cysts 11.7
27 lethal congenital contracture syndrome 1 11.5
28 tyrosinemia, type i 11.5
29 hepatitis c virus 11.5
30 liver sarcoma 11.4
31 hepatoid adenocarcinoma 11.3
32 pityriasis rotunda 11.3
33 hepatocellular clear cell carcinoma 11.3
34 leukoencephalopathy, cerebral calcifications, and cysts 11.3
35 lethal congenital contracture syndrome 11.2
36 gastrointestinal system cancer 11.1 AFP CTNNB1 HRAS MET PIK3CA TP53
37 hepatitis 11.1
38 lung large cell carcinoma 11.1
39 ovarian cancer 11.1 CASP8 CTNNB1 MET PIK3CA TERT TP53
40 nasopharyngeal carcinoma 11.0 CTNNB1 HRAS PIK3CA TERT TP53 VEGFA
41 thyroid cancer 11.0 CTNNB1 HRAS MET PIK3CA TERT TP53
42 lung cancer susceptibility 3 11.0 CASP8 CTNNB1 HRAS MET PIK3CA TERT
43 cholestasis, progressive familial intrahepatic, 2 11.0
44 citrullinemia, type ii, adult-onset 11.0
45 ovarian cancer 1 11.0 CTNNB1 HRAS PIK3CA TP53 VEGFA
46 female reproductive organ cancer 11.0 CTNNB1 HRAS PIK3CA TP53 VEGFA
47 cell type cancer 11.0 AFP CTNNB1 HRAS TP53 VEGFA
48 malignant glioma 11.0 CASP8 MET TERT TP53 VEGFA
49 esophageal basaloid squamous cell carcinoma 11.0 AXIN1 CTNNB1 TP53
50 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.0 CTNNB1 PIK3CA TP53

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Symptoms via clinical synopsis from OMIM:

53
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer


Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

55 31 (show all 49)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 55 31 occasional (7.5%) Occasional (29-5%) HP:0012378
2 dyspnea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002094
3 fever 55 31 occasional (7.5%) Occasional (29-5%) HP:0001945
4 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
5 diarrhea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002014
6 bone pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002653
7 epigastric pain 55 31 frequent (33%) Frequent (79-30%) HP:0410019
8 hypotension 55 31 very rare (1%) Very rare (<4-1%) HP:0002615
9 hepatomegaly 55 31 hallmark (90%) Very frequent (99-80%) HP:0002240
10 type ii diabetes mellitus 55 31 frequent (33%) Frequent (79-30%) HP:0005978
11 portal hypertension 55 31 hallmark (90%) Very frequent (99-80%) HP:0001409
12 hypokalemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002900
13 hypoglycemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001943
14 ascites 55 31 occasional (7.5%) Occasional (29-5%) HP:0001541
15 anemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001903
16 neoplasm 55 31 occasional (7.5%) Occasional (29-5%) HP:0002664
17 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
18 elevated hepatic transaminases 55 31 frequent (33%) Frequent (79-30%) HP:0002910
19 thrombocytopenia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001873
20 jaundice 55 31 occasional (7.5%) Occasional (29-5%) HP:0000952
21 anorexia 55 31 frequent (33%) Frequent (79-30%) HP:0002039
22 thrombocytosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001894
23 hyponatremia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002902
24 hypercalcemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003072
25 internal hemorrhage 55 31 occasional (7.5%) Occasional (29-5%) HP:0011029
26 esophageal varix 55 31 frequent (33%) Frequent (79-30%) HP:0002040
27 venous insufficiency 55 31 frequent (33%) Frequent (79-30%) HP:0005293
28 liver abscess 55 31 very rare (1%) Very rare (<4-1%) HP:0100523
29 hyperbilirubinemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002904
30 abdominal distention 55 31 frequent (33%) Frequent (79-30%) HP:0003270
31 polycythemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001901
32 edema of the lower limbs 55 31 occasional (7.5%) Occasional (29-5%) HP:0010741
33 hypoalbuminemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0003073
34 poor appetite 55 31 occasional (7.5%) Occasional (29-5%) HP:0004396
35 abnormality of the rectum 55 31 frequent (33%) Frequent (79-30%) HP:0002034
36 metabolic alkalosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0200114
37 mood changes 55 31 occasional (7.5%) Occasional (29-5%) HP:0001575
38 hepatic encephalopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002480
39 abnormality of glycoprotein metabolism 55 31 occasional (7.5%) Occasional (29-5%) HP:0004367
40 budd-chiari syndrome 55 31 very rare (1%) Very rare (<4-1%) HP:0002639
41 hepatic necrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002605
42 anasarca 55 31 occasional (7.5%) Occasional (29-5%) HP:0012050
43 hemobilia 55 31 occasional (7.5%) Occasional (29-5%) HP:0100762
44 abnormality of the liver 55 Very frequent (99-80%)
45 hepatocellular carcinoma 31 HP:0001402
46 abnormality of the hepatic vasculature 55 Very frequent (99-80%)
47 constitutional symptom 55 Occasional (29-5%)
48 micronodular cirrhosis 31 HP:0001413
49 subacute progressive viral hepatitis 31 HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


malaise, icterus, fever, abdominal pain, gastrointestinal gas, nausea and vomiting, heartburn, dyspepsia, diarrhea, constipation, hepatosplenomegaly

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 IGF2R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 IGF2R PEG10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.9 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.9 PEG10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.9 APC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 IGF2R PEG10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.9 PEG10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.9 PEG10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.9 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.9 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 PIK3CA CTNNB1 APC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.9 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.9 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.9 APC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.9 IGF2R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.9 IGF2R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 PEG10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.9 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 APC PEG10 PIK3CA CTNNB1 IGF2R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.9 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.9 CTNNB1 IGF2R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.9 APC CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.9 CTNNB1
29 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 APC CDKN3 VEGFA CTNNB1 HRAS

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

43 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 APC CASP8 AXIN1 CTNNB1 HRAS FGL1
2 cellular MP:0005384 10.44 VEGFA AXIN1 APC CASP8 HNF1A CTNNB1
3 endocrine/exocrine gland MP:0005379 10.4 APC CASP8 AFP HRAS HNF1A CTNNB1
4 behavior/neurological MP:0005386 10.38 VEGFA AFP AXIN1 APC HNF1A CTNNB1
5 cardiovascular system MP:0005385 10.38 VEGFA AXIN1 APC CASP8 CTNNB1 HRAS
6 homeostasis/metabolism MP:0005376 10.38 VEGFA AFP APC CASP8 HNF1A CTNNB1
7 mortality/aging MP:0010768 10.38 AFP APC CASP8 AXIN1 HNF1A CTNNB1
8 digestive/alimentary MP:0005381 10.27 VEGFA AXIN1 APC HNF1A CTNNB1 HRAS
9 embryo MP:0005380 10.27 VEGFA AXIN1 APC CASP8 CTNNB1 IGF2R
10 neoplasm MP:0002006 10.21 APC CASP8 AFP HRAS CTNNB1 MTUS1
11 craniofacial MP:0005382 10.19 VEGFA AXIN1 APC CTNNB1 HRAS IGF2R
12 liver/biliary system MP:0005370 10.19 AFP APC CASP8 HNF1A CTNNB1 FGL1
13 nervous system MP:0003631 10.14 VEGFA AXIN1 APC CASP8 CTNNB1 MET
14 integument MP:0010771 10.13 VEGFA APC HNF1A CTNNB1 CASP8 HRAS
15 muscle MP:0005369 10.06 VEGFA APC CASP8 HNF1A CTNNB1 MET
16 limbs/digits/tail MP:0005371 10.05 VEGFA AXIN1 APC CTNNB1 MET IGF2R
17 renal/urinary system MP:0005367 10 APC CASP8 AXIN1 CTNNB1 HRAS HNF1A
18 no phenotypic analysis MP:0003012 9.97 VEGFA APC HNF1A CTNNB1 HRAS MET
19 normal MP:0002873 9.97 VEGFA AXIN1 APC CTNNB1 HRAS MET
20 reproductive system MP:0005389 9.85 VEGFA AFP AXIN1 APC HNF1A CTNNB1
21 respiratory system MP:0005388 9.61 VEGFA AXIN1 CASP8 CTNNB1 HRAS IGF2R
22 skeleton MP:0005390 9.36 VEGFA AXIN1 APC HNF1A CTNNB1 HRAS

Drugs & Therapeutics for Hepatocellular Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Feridex I.V. 17 FERUMOXIDES Advanced Magnetics February 1996
2
Nexavar 17 45 SORAFENIB TOSYLATE Bayer/Onyx December 2005

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 552)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2 198153-51-4 5360545
2
Ribavirin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 36791-04-5 37542
3
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
4
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
5
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 38904 498142
6
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
7
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 8008-53-5
8
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 284461-73-0 216239 406563
9
Cefazolin Approved Phase 4 25953-19-9 33255 656510
10
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
11
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
12
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
13
Coal tar Approved Phase 4,Phase 3,Phase 2 8007-45-2
14
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2 7553-56-2 807
15
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
16
Nadolol Approved Phase 4 42200-33-9 39147
17
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
18
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 2767 441203 84093
21
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
22
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
23
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
26
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
27
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 215647-85-1, 99210-65-8
28
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
29
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
31
Dalteparin Approved Phase 4,Phase 2,Phase 3 9005-49-6
32
Dipyridamole Approved Phase 4 58-32-2 3108
33
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 46507594 772
34 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3 9041-08-1
35
Warfarin Approved Phase 4 81-81-2 54678486 6691
36
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
37
Thymalfasin Approved, Investigational Phase 4,Phase 2 62304-98-7
38
Ledipasvir Approved Phase 4,Phase 3 1256388-51-8 67505836
39
Sofosbuvir Approved Phase 4,Phase 3,Phase 2 1190307-88-0 45375808
40
Norepinephrine Approved Phase 4 51-41-2 439260
41
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
42
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
43
Desflurane Approved Phase 4 57041-67-5 42113
44
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
45
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
46
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
47
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 4091 14219
48
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
50
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 1655)

# Name Status NCT ID Phase Drugs
1 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
2 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
3 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
4 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
5 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
6 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
7 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
8 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
9 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
10 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
11 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
12 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
13 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
14 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
15 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
16 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
17 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
18 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
19 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
20 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
21 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
22 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
23 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
24 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
25 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
26 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
27 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
28 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
29 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
30 Drug-eluting Bead in Hepatocellular Carcinoma Completed NCT01332669 Phase 4
31 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
32 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
33 Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). Completed NCT01798160 Phase 4
34 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4 Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
35 Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma Completed NCT00829465 Phase 4 Licartin
36 Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin
37 Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) Completed NCT01203787 Phase 4 Sorafenib Standard Dosing Regimen;Sorafenib Ramp-Up Regimen
38 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
39 Hepatic Xenetix-CT Perfusion Completed NCT01639703 Phase 4 Xenetix-CT perfusion imaging
40 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4 pegylated interferon alpha 2a and plus ribavirin;pegylated interferon alpha 2a and plus ribavirin
41 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
42 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy Completed NCT01770431 Phase 4 Huaier Granule
43 A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC Completed NCT01263002 Phase 4 clevudine, Adefovir
44 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
45 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) Completed NCT00397540 Phase 4
46 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
47 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Completed NCT03007225 Phase 4 Trans-arterial chemoembolization (TACE);TACE with Drug Eluting Beads procedure
48 Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE Completed NCT00936689 Phase 4
49 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
50 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: carcinoma, hepatocellular

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 28 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53
2 Neoplasm of the Liver 28

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

38
Liver, Endothelial, T Cells, Testes, Bone, Lung, Skin

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 9801)
# Title Authors Year
1
Overexpression of Pyruvate dehydrogenase E1a subunit Inhibits Warburg effect and Induces Cell Apoptosis through Mitochondria-mediated Pathway in Hepatocellular Carcinoma. ( 29444744 )
2018
2
Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. ( 29450606 )
2018
3
Glycogen synthase kinase-3I^ inhibition promotes lysosome-dependent degradation of c-FLIP<sub>L</sub>in hepatocellular carcinoma. ( 29445085 )
2018
4
Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma. ( 29448301 )
2018
5
Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma. ( 29446997 )
2018
6
Efficacy of<sup>125</sup>I Versus Non-<sup>125</sup>I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )
2018
7
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. ( 29449645 )
2018
8
Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. ( 28892201 )
2018
9
Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedurea88- A Nationwide Survey in Japan. ( 29445059 )
2018
10
Subacute invasive aspergillosis associated with sorafenib therapy for hepatocellular carcinoma. ( 29370392 )
2018
11
Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. ( 29416599 )
2018
12
Defining Optimal Surgical Treatment for Recurrent Hepatocellular Carcinoma. -A Propensity Score Matched Analysis. ( 29451360 )
2018
13
Hepatocellular carcinoma surveillance with ultrasound-cost effectiveness, high-risk populations, uptake. ( 29446324 )
2018
14
Hepatic Paragonimiasis Mimicking Hepatocellular Carcinoma. ( 29340921 )
2018
15
Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/I^-catenin pathway. ( 29445127 )
2018
16
Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. ( 29329568 )
2018
17
Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. ( 29445139 )
2018
18
Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. ( 29367206 )
2018
19
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. ( 29327075 )
2018
20
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. ( 29452208 )
2018
21
Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. ( 29444653 )
2018
22
Sex-specific analysis post-liver transplantation in hemochromatosis with aplastic anemia and hepatocellular carcinoma. ( 29404507 )
2018
23
Rottlerin upregulates DDX3 expression in hepatocellular carcinoma. ( 29203243 )
2018
24
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
25
Endoscopic ultrasound-guided fine-needle aspiration of portal vein thrombosis in patients with chronic liver disease and suspicion of hepatocellular carcinoma. ( 29420366 )
2018
26
Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma. ( 29175326 )
2018
27
Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins. ( 29425759 )
2018
28
High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. ( 29399285 )
2018
29
NFI_B mediated elevation of KCNJ11 promotes tumor progression of hepatocellular carcinoma through interaction of lactate dehydrogenase A. ( 29108994 )
2018
30
STK17B promotes carcinogenesis and metastasis via AKT/GSK-3I^/Snail signaling in hepatocellular carcinoma. ( 29445189 )
2018
31
Angiomyolipoma of the Liver without a Fat Component, Mimicking a Hepatocellular Carcinoma. ( 29361814 )
2018
32
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( 29117515 )
2018
33
Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy. ( 29445087 )
2018
34
Non-ionic iodinated contrast-induced sialadenitis with parotid gland sparing in patient of hepatocellular carcinoma. ( 29367371 )
2018
35
A human-specific switch of alternatively spliced<i>AFMID</i>isoforms contributes to<i>TP53</i>mutations and tumor recurrence in hepatocellular carcinoma. ( 29449409 )
2018
36
ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. ( 29448306 )
2018
37
Pin1 impairs microRNA biogenesis by mediating conformation change of XPO5 in hepatocellular carcinoma. ( 29445125 )
2018
38
Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. ( 29449614 )
2018
39
Knockdown of COBRA1 decreases the proliferation and migration of hepatocellular carcinoma cells. ( 28112367 )
2017
40
miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. ( 28529562 )
2017
41
Aberrant CDX2 expression in hepatocellular carcinomas: an important diagnostic pitfall. ( 28089540 )
2017
42
Fusaric Acid Induces DNA Damage and Post-Translational Modifications of p53 in Human Hepatocellular Carcinoma (HepG2 ) Cells. ( 28387973 )
2017
43
Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. ( 28333958 )
2017
44
Protein arginine N-methyltransferase 1 promotes the proliferation and metastasis of hepatocellular carcinoma cells. ( 28231732 )
2017
45
The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. ( 28862757 )
2017
46
Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721. ( 28143959 )
2017
47
Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. ( 28621228 )
2017
48
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. ( 28052155 )
2017
49
AKT activation was not essential for hepatocellular carcinoma cell survival under glucose deprivation. ( 28085697 )
2017
50
miR-217 suppresses proliferation, migration, and invasion promoting apoptosis via targeting MTDH in hepatocellular carcinoma. ( 28184926 )
2017